跳至主要内容
临床试验/NCT02952963
NCT02952963已完成4 期

Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Hvidovre University Hospital1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
8
试验地点
1
主要终点
GLP-1 secretion (evaluated by iAUC)

研究概览

简要总结

The purpose of this study is to examine the efffects of bile acid and bile acids sequestrants on GLP-1 secretion, in patients after Roux-en-Y gastric bypass.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Uncomplicated RYGB performed minimum 3 months prior to the study.
  • Fasting glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB

排除标准

  • Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol 3 months after RYGB
  • Dysregulated thyroid diseases, use of antithyroid treatment.
  • Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.
  • Complications to RYGB. Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake)
  • Cholecystectomy.

研究组 & 干预措施

Chenodeoxycholic Acid

Experimental

Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.

干预措施: Chenodeoxycholic Acid (Drug)

Chenodeoxycholic Acid and Colesevelam

Experimental

Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.

干预措施: Chenodeoxycholic Acid (Drug)

Chenodeoxycholic Acid and Colesevelam

Experimental

Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.

干预措施: Colesevelam (Drug)

结局指标

主要结局

GLP-1 secretion (evaluated by iAUC)

时间窗: -10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes after medicin intake.

次要结局

  • C-peptide secretion(-10, -5, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • CCK secretion(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Glucose levels(-10, -5, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Total ghrelin(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Total bile acid secretion(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Bile acids fractions / FGF-19 concentrations(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Appetite measurements (VAS-score)(-10, 30, 60, 120, 180 and 240 minutes)
  • PYY secretion(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Glucagon secretion(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • GIP secretion(-10, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)
  • Insulin secretion(-10, -5, 0, 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 240 minutes)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Maria Saur Svane

MD, Principal Investigator

Hvidovre University Hospital

研究点 (1)

Loading locations...

相似试验

Effect of Bile Acids and Bile Acid Sequstrants on... | 临床试验